Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $22.66, for a total value of $22,660.00. Following the sale, the chief financial officer directly owned 23,000 shares of the company's stock, valued at approximately $521,180. This trade represents a 4.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Benjamin Hohl also recently made the following trade(s):

• On Friday, June 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.91, for a total transaction of $67,957.50.
• On Tuesday, May 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.18, for a total transaction of $52,585.00.
• On Monday, April 28th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.69, for a total value of $60,742.50.

Enliven Therapeutics Stock Up 2.4%

Shares of NASDAQ:ELVN traded up $0.55 during trading on Monday, hitting $23.00. The stock had a trading volume of 416,268 shares, compared to its average volume of 366,756. The company has a market capitalization of $1.13 billion, a PE ratio of -11.98 and a beta of 0.83. The firm's fifty day moving average is $19.77 and its 200 day moving average is $20.26. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

ELVN has been the subject of a number of recent analyst reports. HC Wainwright upped their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. The Goldman Sachs Group began coverage on Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 target price for the company. Robert W. Baird lifted their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a report on Monday, June 16th. Finally, Jones Trading decreased their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $41.20.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its stake in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after acquiring an additional 1,114 shares during the last quarter. GAMMA Investing LLC boosted its stake in Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after purchasing an additional 2,630 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Enliven Therapeutics during the 1st quarter valued at about $60,000. KLP Kapitalforvaltning AS bought a new stake in Enliven Therapeutics during the 4th quarter valued at about $97,000. Finally, BNP Paribas Financial Markets bought a new stake in Enliven Therapeutics during the 4th quarter valued at about $112,000. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.